The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.
Join Christine Bangert and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.
Highlights from the ADVENT educational symposium at EADV 2024 where Professors Eric Simpson, Stephan Weidinger, and Marjolein de Bruin-Weller explored the local and systemic effects of type 2 inflammation in AD and potential benefits of early intervention with regard to disease modification.
Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, and discuss preclinical findings.
Join experts Henrik Watz and Mona Bafadhel for an educational symposium exploring the role of type 2 cytokines in COPD and delve into the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden.
Presentation highlights from the ADVENT symposium on disease remission in CRSwNP at the 42nd Congress of the International Society of Inflammation and Allergy of the Nose and 24th Congress of the International Rhinologic Society in Tokyo, Japan.
Presentation highlights from the ADVENT symposium on smell loss and nasal congestion in CRSwNP at the 42nd Congress of the International Society of Inflammation and Allergy of the Nose and 24th Congress of the International Rhinologic Society in Tokyo, Japan.
Drs Sarina Elmariah and Mona Shahriari discuss the diagnostic considerations for atopic dermatitis and prurigo nodularis and uncover how clinical signs and itch in these diseases are impacted by type 2 inflammation.
Drs. Stephen Rennard and Igor Barjaktarevic discuss the diverse clinical aspects of COPD, emphasizing the role of inflammation and the importance of biomarker assessments in guiding management strategies of recognizing the heterogeneity of COPD.
Join Drs. James Del Rosso and Raj Chovatiya for an education program to explore the impact, contribution, and diagnosis of type 2 inflammation on atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.
ADVENT is a medical education program dedicated to Type 2 Inflammation across multiple therapeutic areas. Registering for ADVENT is free and unlocks unlimited access to exclusive features and a wealth of content relevant to the practice of Dermatology, Pulmonology, Rhinology, and Gastroenterology. Sign up now!
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.
All rights reserved.
MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.